Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck.

Authors :: Kasi PM
Source :: The oncologist [Oncologist] 2022 May 06; Vol. 27 (5), pp. 336-337.
Publication Year :: 2022

Subjects :: Antineoplastic Combined Chemotherapy Protocols
Cetuximab therapeutic use
Humans
Squamous Cell Carcinoma of Head and Neck
Carcinoma, Squamous Cell drug therapy
Colorectal Neoplasms drug therapy
Head and Neck Neoplasms drug therapy

Full Text Access

Tools